Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA
September 14, 2017 at 15:58 PM EDT
Avastin is South San Francisco-based Genentech's best-selling cancer drug — and the second-biggest cancer drug worldwide. Now Amgen will eat into some of those sales.
